The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Academic Article uri icon

Overview

abstract

  • Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against superficial skin cancers. These two modalities appear to complement each other, hence achieving local and systemic tumor control.

publication date

  • September 24, 2013

Identity

PubMed Central ID

  • PMC3881106

Scopus Document Identifier

  • 77954514970

Digital Object Identifier (DOI)

  • 10.4049/jimmunol.0902997

PubMed ID

  • 24404422

Additional Document Info

volume

  • 2

issue

  • 10